Remote Patient Monitoring Opportunities for Pharma Markets, 2021 Thematic Research Report – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Remote Patient Monitoring – Opportunities for Pharma – Thematic Research” report has been added to ResearchAndMarkets.com’s offering.
This report assesses how RPM, such as wearables, portables, mobile health (mHealth), and telemedicine can be used across the pharma value chain from drug development, post approval, sales and marketing, and end users.
It provides an evaluation of the main opportunities and challenges to the use of RPM, as well as an overview of the current landscape, including changes to regulatory and reimbursement policies.
The report also includes an analyses of RPM-related deals and jobs and the impact of COVID-19 on virtual trials, telemedicine, and physician use of remote monitoring technologies. Pharma-specific case studies in RPM are also included.
Summary
Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, carers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary.
RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures.
Scope
- Key players in the RPM space, with a focus on technology providers and pharma adopters where applicable. The report focuses on any remote monitoring technologies that big pharma has integrated into RPM projects and solutions.
- Thematic briefing which explores different types of RPM in more detail, including wearables, portable devices, mHealth, and telemedicine.
- Key trends impacting the RPM space. Industry trends include the impact of COVID-19 on clinical trials and digital health innovation, how RPM is driving value-based care and increased patient empowerment, and the impact of increased burden of chronic diseases. Technology trends include the role of wearable technology, mHealth, telemedicine, Big Data and artificial intelligence (AI), and cybersecurity. Regulatory trends include the lack of regulatory frameworks for virtual trials and guidelines issues during COVID-19 to support continuation of clinical research.
- Opportunities and challenges for pharma: Opportunities include such changing regulations, continued acceptance of digital technologies, increased collaborations, patient support programs, and value-based care. Challenges include data privacy and security, interoperability, design challenges, and skills shortages.
- Value chain looking at how RPM can be used across the pharma value chain, from drug discovery and development, post drug approval, sales and marketing, and patient use.
- Industry analysis with an analysis of virtual trials including those generating real-world evidence, use of telemedicine during the pandemic, analysis of mobile apps from pharma, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
- Profiles of private and public companies in the RPM space.
Key Topics Covered:
Executive Summary
- Players
- Thematic Briefing
Trends
- Healthcare Trends
- Technology Trends
- Regulatory trends
- Macroeconomic Trends
Opportunities and Challenges for Pharma
- Value Chain
- Drug Discovery and Development
- Post Drug Approval
- Sales and Marketing
- End Users
Industry Analysis
- Virtual Clinical Trials Analysis
- Use of RPM-Derived Real-World Evidence in Post-Marketing Studies
- Increased Use of Telemedicine During the COVID-19 Pandemic
- Analysis of Mobile Apps from Pharma
- Analysis of RPM-Related Jobs in Pharma
- Physician Trends in Remote Monitoring Technologies and the Impact of COVID-19 on Usage
Deals Analysis
- Mergers and Acquisitions
- Strategic Partnerships
- Funding Deals
Pharma Case Studies
- Genentech Telemedicine-Based Patient Support Programs
- Evidation and Merck: Digital Monitoring with Focus on Alzheimer’s Disease
- Biobeat Collaborates with Amwell and Amgen to Offer Comprehensive Wearable RPM Services
- Roche Leads the Biopharmaceutical Industry in Terms of Digital Biomarker Research and Investment
Jobs Analysis
- Healthcare Industry Polls
- Social Media Influencers
- Companies
- Public Pharma Companies
- Private Pharma Companies
- Public Technology Companies
- Private Technology Companies
Companies Mentioned
- Johnson & Johnson
- Pfizer
- Roche
- Novartis
- Takeda
- AbbVie
- AstraZeneca
- Sanofi
- GlaxoSmithKline
- Eli Lilly
- AliveCor
- Empatica
- Livongo
- Omron
- Teladoc
- Amwell
- Aural Analytics
- Evidation
- Huma
- Science37
- Medable
- THREAD
- AiCure
- Akili
- Babylon
- Biobeat
- Qardio
- Biofourmis
- Thirty Madison
- Doctolib
- Lightship
- Studies&Me
For more information about this report visit https://www.researchandmarkets.com/r/lc570h
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
